Johnson & Johnson's fourth-quarter and full-year 2014 earnings call presented a mixed picture with several positive and negative factors that could influence the stock price in the short term.

### Positive Factors:
- **Strong Operational Performance**: Despite currency headwinds, Johnson & Johnson reported operational sales growth of 3.9% in Q4 and 6.1% for the full year, exceeding initial guidance[3].
- **Pharmaceutical Segment Growth**: The Pharmaceutical segment saw a 13.9% sales increase in Q4, driven by new products like OLYSIO, XARELTO, and IMBRUVICA[3].
- **Innovation Pipeline**: The company highlighted a robust pipeline with several promising products and line extensions, including potential breakthrough medications like esketamine and daratumumab[3].
- **Financial Strength**: Johnson & Johnson maintained a strong financial position, with $14.7 billion in free cash flow and a commitment to return value to shareholders[3].

### Negative Factors:
- **Currency Impact**: The significant strengthening of the U.S. dollar against major currencies is expected to negatively impact sales and earnings in 2015, with an estimated 5.5% reduction in sales growth rate and a $0.42 per share impact on EPS[3].
- **Special Items and One-Time Charges**: The Q4 results included a $1.1 billion after-tax charge for special items, which negatively impacted EPS by $0.38 per share[3].
- **Biosimilar and Generic Competition**: The company faces upcoming biosimilar competition for REMICADE in Europe and generic competition for INVEGA, which could impact future sales[3].
- **Moderate EPS Growth Outlook**: The adjusted EPS guidance for 2015, excluding intangible amortization and special items, indicates a modest growth rate of 2.3% to 4.7% on a constant currency basis[3].

### Conclusion:
Given the mixed signals from the earnings call, the short-term impact on Johnson & Johnson's stock price is likely to be neutral to slightly negative due to the significant currency headwinds and upcoming competitive pressures. However, the company's strong operational performance, robust innovation pipeline, and financial strength provide a solid foundation for long-term growth.

**Rating: 0**